ABSTRACT
One hundred sixty-six elderly depressed patients were recruited from six hospital centers and entered in a double-blind, randomized, parallel group comparative study of conventional and controlled-release formulations of trazodone. Patients received a single nighttime dose of 100 mg for 1 week, followed by 3 weeks of 200 mg or less, depending upon tolerance. Efficacy was measured using the modified Hamilton depression rating scale and global assessments of the severity of depression and improvement relative to baseline. Both treatments were equally effective with 39 (68%) patients completing 4 weeks of treatment with the conventional formulation and 41 (77%) patients completing 4 weeks treatment with the controlled-release formulation rated as very much improved. Sleep improved shortly after initiation of treatment in most patients and there were no significant differences between groups. There was a tendency for fewer side effects to be recorded during the first week of treatment in patients receiving the controlled-release formulation but no difference reached statistical significance.
Subject(s)
Depressive Disorder/drug therapy , Trazodone/administration & dosage , Aged , Aged, 80 and over , Delayed-Action Preparations , Double-Blind Method , Female , Humans , Male , Multicenter Studies as Topic , Random Allocation , Trazodone/adverse effects , Trazodone/therapeutic useABSTRACT
Chlormethiazole and thioridazine were found to be equally effective in the management of the agitational component of agitated confusional states in the elderly. Confusion and nocturnal awakening were found to be controlled more effectively with chlormethiazole than with thioridazine. Chlormethiazole treatment also resulted in significant reductions in physical disability as assessed by the Clifton Behaviour Rating Scale. A greater incidence of adverse effects was associated with thioridazine treatment.
